Trials
Search / Trial NCT06424288

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

Launched by BOEHRINGER INGELHEIM · May 21, 2024

Trial Information

Current as of February 19, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for heart failure. Specifically, it aims to find out if a medication called BI 690517, when taken together with empagliflozin, can help improve symptoms in adults aged 18 and older who have heart failure. To join the study, participants should have a specific type of heart failure, known as reduced ejection fraction, with at least 40% heart function. They will be randomly assigned to one of two groups: one group will receive the combination of BI 690517 and empagliflozin, while the other group will receive a placebo (a dummy pill) along with empagliflozin.

Participants can stay in the study as long as the treatment is helping them and they can handle it. Throughout the trial, they will have regular check-ups with their doctors to monitor their health and any side effects. The study does not have a set end date; it will continue until enough information is gathered to determine if the treatment is effective. If you or someone you know has heart failure and meets the eligibility criteria, it might be an opportunity to contribute to important research while receiving care.

Gender

ALL

Eligibility criteria

  • Inclusion criteria:
  • 1. At least 18 years old and at least of the legal age of consent in countries where it is greater than 18 years
  • 2. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
  • 3. Male or female participants. Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per International Conference on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of their use is provided in the participant information
  • 4. Chronic Heart failure (HF) diagnosed at least 3 months before Visit 1, and in New York Heart Association (NYHA) class II-IV at Visit 1, with left ventricular ejection fraction (LVEF) ≥40% per local reading. A historical LVEF may be used if it was measured within 12 months prior to Visit 1, or the LVEF may be measured after study consent has been obtained and before randomisation at Visit 2
  • 5. Presence of structural heart abnormality (confirmed by any imaging modality; i.e. echocardiography at Visit 1, as defined by left ventricular hypertrophy or left atrial enlargement). Historical imaging may be used if performed within 12 months prior to Visit 1, or imaging may be completed after study consent has been obtained and before Visit 2
  • 6. Elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) at Visit 1, analysed at the central laboratory at Visit 1:
  • 1. in participants with body mass index (BMI) \<27 kg/m²: ≥300 pg/mL for participants without atrial fibrillation (Afib) or atrial flutter (Aflutter) (at Visit 1 electrocardiogram (ECG)) and ≥900 pg/mL for participants with Afib or Aflutter (at Visit 1 ECG)
  • 2. in participants with BMI ≥27 kg/m² to \<35 kg/m²: ≥220 pg/mL for participants without Afib or Aflutter (at Visit 1 ECG) and ≥660 pg/mL for participants with Afib or Aflutter (at Visit 1 ECG)
  • 3. in participants with BMI ≥35 kg/m²: ≥125 pg/mL for participants without Afib or Aflutter (at Visit 1 ECG) and ≥375 pg/mL for participants with Afib or Aflutter (at Visit 1 ECG)
  • 7. At least one of the following:
  • Currently treated with diuretic therapy e.g. loop diuretics or thiazides, and on a stable dose for at least 1 week prior to Visit 1
  • Documented hospitalisation for HF within 6 months prior to Visit 1
  • Elevated NT-proBNP at Visit 1, analysed at the central laboratory at Visit 1
  • in participants without Afib or Aflutter (at Visit 1 ECG): ≥900 pg/mL
  • for participants with Afib or Aflutter (at Visit 1 ECG): ≥1800 pg/mL
  • Urine albumin-to-creatinine ratio (UACR) ≥30 mg/g, analysed at the central laboratory at Visit 1
  • 8. Treated according to best possible standard of care (SOC) (disregarding Sodium-dependent glucose co-transporter 2 inhibitors (SGLT2is) and Mineralocorticoid receptor antagonists (MRAs)) in accordance with applicable HF local/international guidelines and judgment of the investigator Further inclusion criteria apply.
  • Exclusion criteria:
  • 1. Treatment with an mineralocorticoid receptor antagonist (MRA) (e.g. spironolactone, eplerenone, finerenone) within 14 days prior to Visit 1 or requiring such treatment before randomisation or planned during the trial based on the judgment of the investigator. Treatment with MRA should not be interrupted with the intention of enrolment into the study
  • 2. Treatment with amiloride, or other potassium-sparing diuretic within 14 days prior to Visit 1 or requiring such treatment before randomisation or planned during the trial based on the judgment of the investigator
  • 3. Receiving the following treatments:
  • a direct renin inhibitor (e.g. aliskiren) at Visit 2
  • more than one angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNI) used simultaneously at Visit 2
  • * In case of acute decompensated HF:
  • i.v. inotrope, i.v. vasodilating drug (e.g. nitrate, nitroprusside), or i.v. natriuretic peptide (e.g. nesiritide, carperitide), or mechanical support (e.g. intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, any ventricular assist device) within 24 hours prior to randomisation (Visit 2)
  • i.v. diuretic with a dose that has been increased/intensified within 6 hours prior to randomisation (a stable dose of an i.v. diuretic is not exclusionary)
  • Systemic mineralocorticoid replacement therapy (e.g. fludrocortisone) at Visit 2
  • Other aldosterone synthase inhibitors, e.g. baxdrostat at Visit 2 or planned during the trial
  • 4. Myocardial infarction (MI), transient ischemic attack (TIA), stroke, coronary artery bypass graft (CABG) surgery, heart valve surgery/intervention or any other major surgery (major according to the investigator's assessment) within 90 days prior to Visit 2, or scheduled for major elective surgery (e.g. hip replacement, coronary artery bypass graft surgery/CABG)
  • 5. Percutaneous coronary intervention (PCI) ( scheduled or unscheduled) or any angiography using iodinated contrast agents in the 7 days prior to Visit 2
  • 6. Heart transplant recipient, awaiting heart transplant, or currently implanted left ventricular assist device (LVAD)
  • 7. Known cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation diseases (e.g. haemochromatosis, Fabry disease), muscular dystrophies, hypertrophic obstructive cardiomyopathy or genetic hypertrophic cardiomyopathy,known pericardial constriction, or cardiomyopathy with potentially reversible cause such as stress or peripartum cardiomyopathy or cardiomyopathy induced by chemotherapy within the 12 months prior to Visit 1 and until Visit 2
  • 8. Acute inflammatory heart disease, such as acute myocarditis, within the 90 days preceding prior to Visit 1 and until Visit 2
  • 9. Known severe valvular heart disease (obstructive or regurgitant), as per investigator's judgment, or valvular heart disease scheduled for surgical or invasive procedures at Visit 1, or anticipated invasive treatment during the study Further exclusion criteria apply.

About Boehringer Ingelheim

Boehringer Ingelheim is a global, research-driven pharmaceutical company dedicated to improving health and quality of life through innovative therapies. Established in 1885 and headquartered in Ingelheim, Germany, the company focuses on the development of prescription medicines in key therapeutic areas, including respiratory diseases, cardiovascular health, oncology, and immunology. Boehringer Ingelheim is committed to advancing medical science through rigorous clinical trials and collaborative research, striving to bring novel treatments to patients while upholding the highest standards of safety and efficacy. With a strong emphasis on sustainability and corporate responsibility, the company aims to make a meaningful impact on global health challenges.

Locations

Tampa, Florida, United States

Norfolk, Virginia, United States

Seattle, Washington, United States

Minneapolis, Minnesota, United States

Dallas, Texas, United States

Ocala, Florida, United States

Coeur D'alene, Idaho, United States

Madrid, , Spain

Truro, , United Kingdom

London, , United Kingdom

Munster, Indiana, United States

Tustin, California, United States

Longview, Texas, United States

Clearwater, Florida, United States

Brandon, Florida, United States

Jacksonville, Florida, United States

Orange, California, United States

Mobile, Alabama, United States

Slidell, Louisiana, United States

San Dimas, California, United States

Hammond, Louisiana, United States

Wellington, Florida, United States

North Kansas City, Missouri, United States

Falls Church, Virginia, United States

Miramar Beach, Florida, United States

Arlington Heights, Illinois, United States

West Des Moines, Iowa, United States

Bossier City, Louisiana, United States

Manalapan, New Jersey, United States

Bronx, New York, United States

Kingwood, Texas, United States

Winchester, Virginia, United States

Waukesha, Wisconsin, United States

Naples, Florida, United States

Oldham, , United Kingdom

Dallas, Texas, United States

Papenburg, , Germany

Bridgewater, New Jersey, United States

Lodz, , Poland

Shreveport, Louisiana, United States

Richmond, Indiana, United States

Bad Friedrichshall, , Germany

Ishikawa, Kanazawa, , Japan

Atlanta, Georgia, United States

Saint Louis, Missouri, United States

Jacksonville, Florida, United States

Boca Raton, Florida, United States

Jacksonville, Florida, United States

Fort Worth, Texas, United States

Indianapolis, Indiana, United States

Ciudad Autonoma Buenos Aires, , Argentina

Greenfield Park, Quebec, Canada

Lüneburg, , Germany

Aichi, Kasugai, , Japan

Chiba, Chiba, , Japan

Siedlce, , Poland

Towson, Maryland, United States

Oshawa, Ontario, Canada

Ypsilanti, Michigan, United States

Sofia, , Bulgaria

Chuo Ku, , Japan

Saint Augustine, Florida, United States

Mississauga, Ontario, Canada

Mckinney, Texas, United States

Winter Park, Florida, United States

Boca Raton, Florida, United States

Rapid City, South Dakota, United States

Mckinney, Texas, United States

Daytona Beach, Florida, United States

Amarillo, Texas, United States

Greensboro, North Carolina, United States

Hallandale Beach, Florida, United States

Pleven, , Bulgaria

Greenville, South Carolina, United States

Tokushima, , Japan

Chula Vista, California, United States

Largo, Florida, United States

Dallas, Texas, United States

Frankfurt, , Germany

Johns Creek, Georgia, United States

Olsztyn, , Poland

Sofia, , Bulgaria

Merrillville, Indiana, United States

Ocala, Florida, United States

Port Charlotte, Florida, United States

Marion, Ohio, United States

Jackson, Tennessee, United States

Mobile, Alabama, United States

Libertyville, Illinois, United States

Park Ridge, Illinois, United States

Wichita, Kansas, United States

Dearborn, Michigan, United States

Lincoln, Nebraska, United States

Amarillo, Texas, United States

Valencia, California, United States

Wesley Chapel, Florida, United States

Jefferson City, Tennessee, United States

Mito Shi, , Japan

Edmonton, , Canada

Kobe Shi, , Japan

Lansing, Michigan, United States

Hamada Shi, , Japan

Madison, Wisconsin, United States

Pleven, , Bulgaria

Pleven, , Bulgaria

Stara Zagora, , Bulgaria

Sarnia, Ontario, Canada

Stoney Creek, Ontario, Canada

St. Jean Sur Richelieu, , Canada

Brandys Nad Labem, , Czechia

Prague 10, , Czechia

Smirice, , Czechia

Berlin, , Germany

Budapest, , Hungary

Azumino Shi, , Japan

Higashiibaraki Gun, , Japan

Kamakura Shi, , Japan

Kanagawa, Yokohama, , Japan

Okayama Shi, , Japan

Saitama Shi, , Japan

Gdynia, , Poland

Kraków, , Poland

Iasi, , Romania

Somerset, New Jersey, United States

Butler, Pennsylvania, United States

Chicago, Illinois, United States

Ciudad Autonoma Buenos Aires, , Argentina

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0